Article Text

Other full case
Cardiac amyloidosis: can advances in diagnostics and treatments improve survival?
  1. Kalai Karthikeyan1,
  2. Nilesh Jagjivan1,
  3. Matthew Lyttelton2,
  4. James Cullen1
  1. 1
    Kettering General Hospital, Cardiology, Rothwell Road, Kettering, NN16 8UZ, UK
  2. 2
    Kettering General Hospital Foundation NHS Trust, Haematology, Rothwell Road, Kettering, NN16 8UZ, UK
  1. Kalai Karthikeyan, drkalai{at}


Amyloidosis is a generalised clinical disorder characterised by extracellular deposition of amyloid fibrils. Symptomatic cardiac amyloidosis is typically associated with light chain (AL) amyloidosis in the western world. Amyloid deposition in the myocardium causes restrictive cardiomyopathy. Cardiac manifestations affect patient’s performance status and limit therapeutic options. We present a case of rapidly progressing cardiac amyloid deposition due to AL amyloidosis presenting with typical features of restrictive cardiomyopathy. We also discuss the advances in non-invasive diagnostic techniques applied in this case and currently available novel treatments. Early diagnosis and better response to novel treatments could potentially improve the overall survival in this group of patients.

View Full Text

Statistics from


  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.